Following an almost two-week long trial, a federal jury in Delaware ruled Merck’s patent for hepatitis C treatments was valid. Merck acquired the drug patent when it purchased Idenix Pharmaceuticals in 2014.
In 2015, Gilead Science’s hit almost $20 billion in revenue from Harvoni and Sovaldi. The jury’s award represents a 10 percent royalty rate from sales of the drugs through this August, according to the report.
Michele Rest, a spokeswoman for Foster City, Calif.-based Gilead Sciences, said the drugmaker disagrees with the verdict and plans to file an appeal, according to the report.
More articles on supply chain:
American Red Cross needs donors amid seasonal blood shortage
Amazon conducts first drone delivery to a customer
Pharma manufacturer Lonza to acquire Capsugel for $5.5B: 4 things to know
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
